Biowaiver extension potential and IVIVC for BCS class II drugs by formulation design: Case study for cyclosporine self-microemulsifying formulation

Archives of Pharmacal Research

Volumn 33, Issue 11, 2010, Pages 1835-1842

  Yang, Su Geun ^a,b  

^a Utah Inha DDS and Advanced Theapeutics Research Center   (South Korea)

^b Inha University School of Medicine   (South Korea)

Author keywords

Biopharmaceutics classification system (BCS); Biowaiver; Cyclosporine; In vitro in vivo correlation (IVIVC); Self microemulsifying drug delivery systems (SMEDDS)

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CORRELATION ANALYSIS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SOLUBILITY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; NONHUMAN;

ABSORPTION; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DOGS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUGS, GENERIC; EMULSIFYING AGENTS; EMULSIONS; IMMUNOSUPPRESSIVE AGENTS; MALE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY;

EID: 78751487071     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-010-1116-2     Document Type: Article

References (43)

1. Araya, H., Tomita, M., and Hayashi, M., The novel formula-tion design of O/W microemulsion for improving the gas-trointestinal absorption of poorly water soluble compounds. Int. J. Pharm., 305, 61-74 (2005).
2. Borhade, V. B., Nair, H. A., and Hegde, D. D., Development and characterization of self-microemulsifying drug delivery system of tacrolimus for intravenous administration. Drug Dev. Ind. Pharm., 35, 619-630 (2009).
3. Chen, Y., Li, G, Wu, X., Chen, Z, Hang, J, Qin, B, Chen, S., and Wang, R., Self-microemulsifying drug delivery system (SMEDDS) of vinpocetine: formulation development and in vivo assessment. Biol. Pharm. Bull., 31, 118-125 (2008).
4. Cheng, C L, Yu, L. X, Lee, H. L., Yang, C Y, Lue, C S., and Chou, C. H., Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur. J. Pharm. Sci., 22, 297-304 (2004).
5. Chiu, Y. Y, Higaki, K, Neudeck, B. L., Barnett, J. L., Welage, L. S., and Amidon, G. L., Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm. Res., 20, 749-756 (2003).
6. Donato, E. M., Martins, L. A., Froehlich, P. E., and Bergold, A. M., Development and validation of dissolution test for lopinavir, a poorly water-soluble drug, in soft gel capsules, based on in vivo data. J. Pharm. Biomed. Anal., 47, 547-552 (2008).
7. Emami, J., In vitro-in vivo correlation: from theory to applications. J. Pharm. Pharm. Sci., 9, 169-189 (2006).
8. Gershanik, T. and Benita, S., Self-dispersing lipid formula-tions for improving oral absorption of lipophilic drugs. Eur. J. Pharm. Biopharm., 50, 179-188 (2000).
9. Gursoy, R. N. and Benita, S., Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed. Pharmacother., 58, 173-182 (2004).
10. Irvine, J. D., Takahashi, L., Lockhart, K., Cheong, J., Tolan, J. W., Selick, H. E., and Grove, J. R., MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J. Pharm. Sci., 88, 28-33 (1999).
11. Ismailos, G., Reppas, C, Dressman, J. B., and Macheras, P., Unusual solubility behaviour of cyclosporin A in aqueous media. J. Pharm. Pharmacol., 43, 287-289 (1991).
12. Jantratid, E., Prakongpan, S., Amidon, G. L., and Dressman, J. B., Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Clin. Pharmacokinet., 45, 385-399 (2006).
13. Kabanov, A. V., Batrakova, E. V., and Miller, D. W., Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv. Drug Deliv. Rev., 55, 151-164 (2003).
14. Kahlweit, M., Microemulsions. Science, 240, 617-621 (1988).
15. Kang, B. K., Lee, J. S, Chon, S. K, Jeong, S. Y, Yuk, S. H, Khang, G., Lee, H. B., and Cho, S. H., Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int. J. Pharm., 274, 65-73 (2004).
16. Koga, K., Takarada, N., and Takada, K., Nano-sized water-in-oil-in-water emulsion enhances intestinal absorption of calcein, a high solubility and low permeability compound. Eur. J. Pharm. Biopharm., 74, 223-232 (2010).
17. Kovacevic, I., Parojcic, J., Homsek, I., Tubic-Grozdanis, M., and Langguth, P., Justification of biowaiver for carbama-zepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simu-lation. Mol. Pharm., 6, 40-47 (2009).
18. Lake, O. A., Olling, M., and Barends, D. M., In vitro/in vivo correlations of dissolution data of carbamazepine immedi-ate release tablets with pharmacokinetic data obtained in healthy volunteers. Eur. J. Pharm. Biopharm., 48, 13-19 (1999).
19. Lawrence, M. J. and Rees, G. D., Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev., 45, 89-121 (2000).
20. Liu, Y, Chen, Z. Q, Zhang, X, Feng, N. P, Zhao, J. H, Wu, S., and Tan, R., An improved formulation screening and optimization method applied to the development of a self-microemulsifying drug delivery system. Chem. Pharm. Bull., 58, 16-22 (2010).
21. Lobenberg, R. and Amidon, G. L., Modern bioavailability, bioequivalence and biopharmaceutics classifcation sys-tem. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm., 50, 3-12 (2000).
22. Masri, M., The generics in transplantation and the rules on their use. Exp. Clin. Transplant., 1, 65-68 (2003).
23. Moore, J. W. and Flanner, H. H., Mathematical comparison of dissolution profiles. Pharm. Technol., 20, 64-74 (1996).
24. Nishimura, H., Hayashi, C, Aiba, T., Okamoto, I., Miyamoto, Y., Nakade, S., Takeda, K., and Kurosaki, Y., Application of the correlation of in vitro dissolution behavior and in vivo plasma concentration profile (IVIVC) for soft-gel capsules-a pointless pursuit? Biol. Pharm. Bull., 30, 2221-2225 (2007).
25. Patel, A. R. and Vavia, P. R., Preparation and in vivo eval-uation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate. AAPS J., 9, E344-E352 (2007).
26. Porter, C. J., Trevaskis, N. L., and Charman, W. N., Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev. Drug Discov., 6, 231-248 (2007).
27. Pouton, C. W., Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-micro-emulsifying' drug delivery systems. Eur. J. Pharm. Sci., 11 Suppl 2, S93-S98 (2000).
28. Rinaki, E., Dokoumetzidis, A., Valsami, G., and Macheras, P., Identification of biowaivers among Class II drugs: theoretical justification and practical examples. Pharm. Res., 21, 1567-1572 (2004).
29. Rossi, R. C, Dias, C. L., Donato, E. M., Martins, L. A., Bergold, A. M., and Froehlich, P. E., Development and validation of dissolution test for ritonavir soft gelatin capsules based on in vivo data. Int. J. Pharm., 338, 119-124 (2007).
30. Shen, H. R., Li, Z. D., and Zhong, M. K., [Preparation and evaluation of self-microemulsifying drug delivery systems containing atorvastatin]. Yao Xue Xue Bao, 40, 982-987 (2005).
31. Spernath, A. and Aserin, A., Microemulsions as carriers for drugs and nutraceuticals. Adv. Colloid Interface Sci., 128-130, 47-64 (2006).
32. Spernath, A., Aserin, A., Ziserman, L., Danino, D., and Garti, N., Phosphatidylcholine embedded microemulsions: phy-sical properties and improved Caco-2 cell permeability. J. Control. Release., 119, 279-290 (2007).
33. Taub, M. E., Kristensen, L., and Frokjaer, S., Optimized con-ditions for MDCK permeability and turbidimetric solubil-ity studies using compounds representative of BCS classes I-IV. Eur. J. Pharm. Sci., 15, 331-340 (2002).
34. Trull, A. K, Tan, K. K, Tan, L., Alexander, G. J., and Jamieson, N. V., Enhanced absorption of new oral cyclosporin micro-emulsion formulation, Neoral, in liver transplant recipients with external biliary diversion. Transplant. Proc., 26, 2977-2978 (1994).
35. Vicosa, A. L., Chatah, E. N., Santos, T. C, Jones, L. F., Jr., Dantas, C. B., Dornelas, C B., Rodrigues, C R., Castro, H. C, Sousa, V. P., Dias, L. R., and Cabral, L. M., Bioequival-ence studies and sugar-based excipients effects on the pro-perties of new generic ketoconazole tablets formulations and stability evaluation by using direct compression method. Pharm. Dev. Technol., 14, 530-539 (2009).
36. Wei, L., Sun, P., Nie, S., and Pan, W., Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Dev. Ind. Pharm., 31, 785-794 (2005).
37. Woo, J. S., Kim, T. S., Park, J. H., and Chi, S. C, Formulation and biopharmaceutical evaluation of silymarin using SMEDDS. Arch. Pharm. Res., 30, 82-89 (2007).
38. Woo, J. S, Song, Y. K, Hong, J. Y, Lim, S. J, and Kim, C K, Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. Eur. J. Pharm. Sci., 33, 159-165 (2008).
39. Wu, W., Wang, Y., and Que, L., Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur. J. Pharm. Biopharm., 63, 288-294 (2006).
40. Yang, S., Gursoy, R. N., Lambert, G., and Benita, S., Enhanced oral absorption of paclitaxel in a novel self-microemul-sifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm. Res., 21, 261-270 (2004).
41. Yang, S. G., Novel Nano Delivery System of Cyclosporin A with Enhanced Stability. Seoul National University, Seoul, (2006).
42. Yang, S. G, Kim, D. D., Chung, S. J, and Shim, C. K, Stable bioavailability of cyclosporin A, regardless of food intake, from soft gelatin capsules containing a new self-nanoemul-sifying formulation. Int. J. Clin. Pharmacol. Ther., 44, 233-239 (2006).
43. Yu, L. X, Amidon, G. L, Polli, J. E, Zhao, H, Mehta, M. U E, Conner, D. P., Shah, V. P., Lesko, L. J., Chen, M. L., Le V. H., and Hussain, A. S., Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res., 19, 921-925 (2002).